Xcell Therapeutics
Financials
Valuation Metrics
Xcell Therapeutics's Market Cap is ₩203B. At end of 2025 it was ₩287B. Ranked #2324 of 2,436 in KR market (top 95%), #1545 of 1,649 on KOSDAQ (top 94%), #228 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 20.30B KRW | KR#2,324/2,436 Sec#228/234 |
| Revenue | 2.64B KRW | KR#2,381/2,436 Sec#212/234 |
| Net Income | -11.31B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 14.92B KRW | KR#2,379/2,436 Sec#230/234 |
| Net Assets | 6.54B KRW | KR#2,385/2,436 Sec#229/234 |
| Employees | 68 | KR#1,884/2,436 Sec#163/234 |
| Value | ||
| P/B | 3.10x | KR#2,129/2,436 Sec#167/234 |
| P/S | 7.69x | KR#2,230/2,436 Sec#153/234 |
| FCF Yield | -51.07% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -172.83% | KR#2,369/2,436 Sec#225/234 |
| ROA | -75.77% | KR#2,373/2,436 Sec#225/234 |
| Op. Margin | -424.39% | KR#2,371/2,436 Sec#205/234 |
| Revenue Growth | 209.78% | KR#63/2,436 Sec#10/234 |
| Financial Health | ||
| Debt Ratio | 228.08% | KR#1,891/2,436 Sec#205/234 |
| Total Debt | 4.60B KRW | KR#1,798/2,436 Sec#174/234 |
| FCF | -10.37B KRW | KR#1,725/2,436 Sec#150/234 |
| Cash | 6.02B KRW | KR#1,915/2,436 Sec#169/234 |
| Current Ratio | 1.88x | KR#1,019/2,436 Sec#115/234 |
| Performance | ||
| 1Y Return | -57.45% | KR#2,217/2,436 Sec#210/234 |
| 1M Return | -0.59% | KR#1,316/2,436 Sec#120/234 |
| From 52W High | -67.32% | KR#2,034/2,436 Sec#178/234 |
| 1Y MDD | -67.40% | KR#1,813/2,436 Sec#150/234 |
| Trading | ||
| Volume | 45,880 shares | KR#1,645/2,436 Sec#153/234 |
| Foreign Own. | 4.60% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -784 KRW | KR—/2,436 Sec—/234 |
| BPS | 378 KRW | KR#2,410/2,436 Sec#230/234 |
Company Info
Excell Therapeutics, established in 2015 and listed on KOSDAQ in 2024 as a technology growth company, specializes in cell culture media. The company primarily manufactures and supplies chemically defined media, 'CellCor', which excludes animal and human-derived substances crucial for the cell and gene therapy industry, from its GMP production facilities. It has developed the cell-customized medium development platform technology XPorT and is expanding its business into advanced biopharmaceuticals. Excell Therapeutics is headquartered in Gangnam-gu, Seoul.